Publications by authors named "E Odongo-Aginya"

Article Synopsis
  • Artemisinin-based combination therapies (ACTs) have been the standard treatment for uncomplicated malaria in Africa for nearly 20 years, but recent studies indicate an increase in mutant parasites linked to reduced treatment effectiveness.
  • The Community Access to Rectal Artesunate for Malaria project studied 697 children with severe malaria in northern Uganda, finding that a significant mutation (C469Y) was more common after the introduction of rectal artesunate, suggesting it enhances resistance.
  • Genome analysis revealed that the C469Y mutation has an indigenous African origin and confirmed that parasites with this mutation show significantly reduced susceptibility to artemisinin, highlighting the urgent need for ongoing monitoring and adherence to treatment protocols to combat the rise of resistant strains.
View Article and Find Full Text PDF

The spread of malarial parasites resistant to first-line treatments such as artemisinin combination therapies is a global health concern. Differentiation-inducing factor 1 (DIF-1) is a chlorinated alkylphenone (1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl) hexan-1-one) originally found in the cellular slime mould Dictyostelium discoideum. We previously showed that some derivatives of DIF-1, particularly DIF-1(+2) (1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl) octan-1-one), exert potent antimalarial activities.

View Article and Find Full Text PDF

Objectives: Artemisinin-resistant Plasmodium falciparum malaria is currently spreading globally, including in Africa. Artemisinin resistance also leads to resistance to partner drugs used in artemisinin-based combination therapies. Sequencing of kelch13, which is associated with artemisinin resistance, culture-based partner drug susceptibility tests, and ELISA-based growth measurement are conventionally used to monitor resistance; however, their application is challenging in resource-limited settings.

View Article and Find Full Text PDF

Background: Artemisinin-resistant Plasmodium falciparum is spreading in Southeast Asia and Africa. In vivo susceptibility to artemisinin is studied by looking at the rate of decline of peripheral parasitemia (parasite clearance half-life). However, parasites that are adhered/sequestered to the endothelium and undetectable in the peripheral blood are not considered in the estimation of parasite clearance.

View Article and Find Full Text PDF

A returned traveler to Uganda presented with a Plasmodium falciparum kelch13 A675V mutant infection that exhibited delayed clearance under artesunate therapy. Parasites were genetically related to recently reported Ugandan artemisinin-resistant A675V parasites. Adequate malaria prevention measures and clinical and genotypic surveillance are important tools to avoid and track artemisinin resistance.

View Article and Find Full Text PDF